31 min listen
How to kill a trial
FromBlood & Cancer
ratings:
Length:
7 minutes
Released:
Nov 17, 2020
Format:
Podcast episode
Description
The Tomosynthesis Mammography Imaging Screening Trial (TMIST) was designed to see if 3-D mammography, or tomosynthesis, could help personalize screening and if 3-D is actually better than the less expensive 2-D mammography. TMIST is the largest breast cancer screening trial in the United States, with a cost of $100 million and a planned enrollment of 165,000 women. There's just one problem. The study is falling short on enrollment of patients and participating sites. Will this mean the death of TMIST? For more details, see coverage of TMIST on Medscape: NCI May 'Kill' Major Mammography Trial, Says Advisor https://www.medscape.com/viewarticle/937918 Email Blood & Cancer at podcasts@mdedge.com.
Released:
Nov 17, 2020
Format:
Podcast episode
Titles in the series (100)
ASH19 special report: Blood & Cancer takes you behind the podium at the American Society of Hematology annual meeting for an in-depth look at the latest developments in anemia and myelodysplastic syndrome, chimeric antigen receptor (CAR) T-cell therapy for mantle cell... by Blood & Cancer